The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000571370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/01/2023
Date registered
Help: Date registered
6/05/2026
Date last updated
Help: Date last updated
6/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase II Trial of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours
Scientific title
Phase II Trial of the Safety and Clinical Activity of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours
Additional trial identifiers [1] 308690 0
None
Universal Trial Number (UTN)
Trial acronym
DART (Deflexifol At Relapse Trial)
Related trial records

Health condition
Health condition(s) studied:
Central Nervous System Tumour 328619 0
Ependymoma 328620 0
Condition category
Condition code
Cancer 325623 325623 0 0
Children's - Brain

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a phase II, multicentre study evaluating the use of Deflexifol in the treatment of children and young adults (greater than 12 months and less than or equal to 21 years) with refractory/recurrent central nervous system (CNS) tumours. This is a follow-up trial to the Phase I trial (ACTRN12623000104651), which has identified the paediatric Recommended Phase 2 Dose (RP2D) for Deflexifol.

Deflexifol is a novel bioequivalent formulation of 5-fluorouracil and leucovorin that has been shown to be safe and effective in adults with advanced/ refractory solid tumours. In this trial, we will evaluate the anti-tumour activity of Deflexifol as a single agent in children.

Phase II (or Part B) will be open to any participants with refractory or recurrent ependymoma that meet the definition of measurable disease. This will consist of ependymoma participants from Phase I (or Part A) who were treated on the RP2D, in conjunction with new participants enrolled in Part B.

Deflexifol will be administered on Days 1 and 15 of a 28 days cycle. Deflexifol (525 mg/m2) will initially be administered via an injection over 3-5 minutes, followed by a 3000 mg/m2 continuous intravenous infusion over 46 hours. Depending on the treating doctor and each participant’s condition, the treating doctor may elect to administer the treatment at home or in hospital.

Participants may receive treatment a minimum of 1 dose and a maximum of one year of study drug, as long as the participant is able to tolerate treatment and is responding to the treatment.
Intervention code [1] 325154 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 333469 0
Overall response rate (ORR, defined as the number of best responses (complete response plus partial response) divided by the number of evaluable participants, according to Response Assessment in Paediatric Neuro-Oncology (RAPNO) criteria for CNS tumours.
Timepoint [1] 333469 0
After 2, 4, 6, 9 and 12 months of treatment; 30 days after last dose of treatment; and annually during follow-up.
Secondary outcome [1] 417190 0
Overall survival calculated as the time from enrolment to date of death.
Timepoint [1] 417190 0
Annual assessment for up to 5 years from end of treatment or time of study discontinuation.
Secondary outcome [2] 417191 0
Progression-free survival calculated as the time from enrolment to date of event defined as the first medical records documented disease progression or death resulting from underlying cancer.
Timepoint [2] 417191 0
Annual assessment for up to 5 years from end of treatment or time of study discontinuation.

Eligibility
Key inclusion criteria
1. Written informed consent.
2. Patients must be greater than 12 months and less than or equal to 21 years of age at the time of study enrolment.
3. Patient must have ependymoma that is recurrent or refractory, previously treated with irradiation therapy, with no known curative therapies or therapy proven to prolong survival with an acceptable quality of life.
4.Only patients with measurable disease as per RAPNO are eligible.
5. Karnofsky performance status greater than or equal to 50 for patients above 16 years old; or Lansky performance status greater than or equal to 50 for patients less than or equal to 16 years old. Patients who are not able to walk due to paralysis, but who are sitting up in a wheelchair, are considered ambulatory for the purpose of performance score assessment.
6. Life expectancy of greater than 6 weeks.
7. Patients receiving corticosteroids will need to be on a stable, or reducing, dose of steroids for at least one week before enrolment.

8. Fully recovered from acute toxic effects of all prior anti-cancer therapy.
8a. Must not have received myelosuppressive chemotherapy within 21 days of start of study treatment (42 days if prior nitrosourea or mitomycin-C).
8b. At least 7 days after the last dose of anti-cancer agents not known to be myelosuppressive. For agents that have known adverse events occurring beyond 7 days after last administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
8c. At least 42 days after the completion of any type of immunotherapy, e.g. tumour vaccines.
8d. At least 21 days after the last dose of a monoclonal antibody, and toxicities related to prior antibody therapy have recovered to less than or equal to grade 1.
8e. At least 6 weeks after the completion of radiation therapy (including cranio-spinal irradiation). If palliative radiotherapy has been administered, then 2 weeks must have lapsed before the patient can commence on this trial, and this lesion cannot be used as the target lesion for assessment of treatment response.
8f. 14 days or more from last long-acting haematopoietic growth factors (e.g. pegfilgrastim) or 7 days for short acting growth factor.

9. Adequate function in bone marrow, renal and liver. Blood pressure within normal range for age.
10. Patient must be or have been previously enrolled in the ZERO Childhood Cancer (ZERO) precision medicine trial or program.
11. Female patient of childbearing potential must have a negative serum or urine pregnancy test at screening and prior to the beginning of each cycle. They must agree to use an effective method of contraception during the study period and for six months after treatment discontinuation.
12. Fertile male patients must use an effective method of contraception during the study period and for six months after treatment discontinuation.
Minimum age
12 Months
Maximum age
21 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Concomitant medications.
1a. Patients who are currently receiving another investigational agent are not eligible.
1b. Patients who are currently receiving other anti-cancer agents are not eligible.
2. Any known Dihydropyrimidine dehydrogenase (DPD) deficiency.
3. Prior solid organ transplantation.
4. Uncontrolled infection.
5. Pregnant or breastfeeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
A single-stage A’hern design will be used to determine the objective response rate to deflexifol in 10 participants. This includes evaluable participants with ependymoma from Phase I (or Part A), who were treated on the Recommended Phase 2 dose (RP2D) with measurable disease. If there is at least 1 response out of 10 in recurrent/refractory ependymoma, which represents a 20% increase in response rate (alpha = 0.01, power 90%, historical response rate P0 = 0%), the treatment regimen will be deemed sufficiently effective to warrant further study in a larger Phase II trial.

Analysis plan:
RAPNO criteria will be tabulated for each evaluation time point.

The incidence of all AEs and SAEs will be summarised separately for treatment groups by system organ class, low level term and/or preferred term. Additionally, the incidence of all AEs and SAEs will be summarised by severity and relationship to study treatment. Participants who terminate the study due to an AE will be listed.

Safety data (haematology, serum chemistry and vital signs) will be summarised with simple descriptive statistics (minimum, maximum and median).

A Statistical Analysis Plan (SAP) details the statistical evaluations. This is based on:
1. Descriptive statistics for safety data (outlined above) based on each dose level
2. PK analysis, per dose level, and anthropometric measures (height, weight, body surface area using the Mosteller formula)
3. Preliminary efficacy analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 23759 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 23760 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 23761 0
John Hunter Children's Hospital - New Lambton
Recruitment hospital [4] 23762 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [5] 23763 0
Monash Children’s Hospital - Clayton
Recruitment hospital [6] 23764 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [7] 23765 0
Perth Children's Hospital - Nedlands
Recruitment hospital [8] 23766 0
Womens and Childrens Hospital - North Adelaide
Recruitment postcode(s) [1] 39204 0
2031 - Randwick
Recruitment postcode(s) [2] 39205 0
2145 - Westmead
Recruitment postcode(s) [3] 39206 0
2305 - New Lambton
Recruitment postcode(s) [4] 39207 0
3052 - Parkville
Recruitment postcode(s) [5] 39208 0
3168 - Clayton
Recruitment postcode(s) [6] 39209 0
4101 - South Brisbane
Recruitment postcode(s) [7] 39210 0
6009 - Nedlands
Recruitment postcode(s) [8] 39211 0
5006 - North Adelaide

Funding & Sponsors
Funding source category [1] 312919 0
Charities/Societies/Foundations
Name [1] 312919 0
Kids with Cancer Foundation
Country [1] 312919 0
Australia
Funding source category [2] 312920 0
Charities/Societies/Foundations
Name [2] 312920 0
Robert Connor Dawes Foundation
Country [2] 312920 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG)
Address
27-31 Wright Street, Clayton VIC 3168
Country
Australia
Secondary sponsor category [1] 314597 0
None
Name [1] 314597 0
Address [1] 314597 0
Country [1] 314597 0
Other collaborator category [1] 282517 0
Individual
Name [1] 282517 0
Dr Marion Mateos - Co-Principal Investigator
Address [1] 282517 0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Country [1] 282517 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 312192 0
Sydney Children’s Hospitals Network Human Research Ethics Committee
Ethics committee address [1] 312192 0
Ethics committee country [1] 312192 0
Australia
Date submitted for ethics approval [1] 312192 0
Approval date [1] 312192 0
10/08/2022
Ethics approval number [1] 312192 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 123798 0
Prof David Ziegler
Address 123798 0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Country 123798 0
Australia
Phone 123798 0
+612 9382 1111
Fax 123798 0
Email 123798 0
Contact person for public queries
Name 123799 0
Robyn Strong
Address 123799 0
ANZCHOG, Hudson Institute of Medical Research, 27-31 Wright St, Clayton VIC 3168
Country 123799 0
Australia
Phone 123799 0
+613 8572 2684
Fax 123799 0
Email 123799 0
Contact person for scientific queries
Name 123800 0
David Ziegler / Dr Marion Mateos
Address 123800 0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Country 123800 0
Australia
Phone 123800 0
+612 9382 1111
Fax 123800 0
Email 123800 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Aggregate results will be made available publicly.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.